KYORIN Holdings Inc (4569) - Financial and Strategic SWOT Analysis Review

  • ID: 4418440
  • SWOT Analysis
  • 39 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Nippon Shinyaku Co Ltd
  • Teijin Ltd
  • MORE
KYORIN Holdings Inc (4569) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

KYORIN Holdings Inc (KYORIN), formerly known as KYORIN Co.,Ltd., is a holding company. Its business activities include controlling, administering and supporting companies, which conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries out the discovery, manufacturing and sale of pharmaceuticals including new ethical drugs, generic drugs and the over-the-counter (OTC) drugs. It also provides consumer healthcare products including beauty and good health products. KYORIN provides product under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. KYORIN is headquartered in Chiyoda-Ku, Tokyo, Japan.

KYORIN Holdings Inc Key Recent Developments

Sep 24, 2018: Kyorin Receives Approval from Japan's Ministry of Health, Labour and Welfare for Vibegron for Overactive Bladder
Aug 28, 2018: Kyorin Receives Approval from Japan's Ministry of Health, Labour and Welfare for Vibegron for Overactive Bladder
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin
Feb 22, 2017: Kyorin Holdings: Establishment of a Representative Office in the Republic of Indonesia
Feb 22, 2017: Kyorin: Change of Representative Director and President at ActivX Biosciences

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Nippon Shinyaku Co Ltd
  • Teijin Ltd
  • MORE
List of Tables
List of Figures
Section 1 - About the Company
KYORIN Holdings Inc - Key Facts
KYORIN Holdings Inc - Key Employees
KYORIN Holdings Inc - Key Employee Biographies
KYORIN Holdings Inc - Major Products and Services
KYORIN Holdings Inc - History
KYORIN Holdings Inc - Company Statement
KYORIN Holdings Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
KYORIN Holdings Inc - Business Description
Business Segment: Consumer Healthcare Business
Overview
Performance
Business Segment: Ethical Pharmaceutical Business
Overview
Performance
R&D Overview
KYORIN Holdings Inc - Corporate Strategy
KYORIN Holdings Inc - SWOT Analysis
SWOT Analysis - Overview
KYORIN Holdings Inc - Strengths
KYORIN Holdings Inc - Weaknesses
KYORIN Holdings Inc - Opportunities
KYORIN Holdings Inc - Threats
KYORIN Holdings Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
KYORIN Holdings Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin
Feb 22, 2017: Kyorin Holdings: Establishment of a Representative Office in the Republic of Indonesia
Feb 22, 2017: Kyorin: Change of Representative Director and President at ActivX Biosciences
Section 6 – Appendix
Methodology
Ratio Definitions
Contact Us
Disclaimer

List of Tables
KYORIN Holdings Inc, Key Facts
KYORIN Holdings Inc, Key Employees
KYORIN Holdings Inc, Key Employee Biographies
KYORIN Holdings Inc, Major Products and Services
KYORIN Holdings Inc, History
KYORIN Holdings Inc, Subsidiaries
KYORIN Holdings Inc, Key Competitors
KYORIN Holdings Inc, Ratios based on current share price
KYORIN Holdings Inc, Annual Ratios
KYORIN Holdings Inc, Interim Ratios
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
KYORIN Holdings Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
KYORIN Holdings Inc, Performance Chart (2014 - 2018)
KYORIN Holdings Inc, Ratio Charts
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Torii Pharmaceutical Co Ltd
  • Teijin Ltd
  • Santen Pharmaceutical Co Ltd
  • Nippon Shinyaku Co Ltd
  • Mochida Pharmaceutical Co Ltd
  • Astellas Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll